Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol

Healthcare resources usage and costs associated to nonvalvular atrial fibrillation (NVAF) were analyzed in Spain. This is an observational and retrospective study on patients with NVAF who started their treatment with apixaban or acenocoumarol between 1 January 2015 and 31 December 2017. 2160 patien...

Full description

Saved in:
Bibliographic Details
Published in:Journal of comparative effectiveness research 2023-08, Vol.12 (8), p.e230007-e230007
Main Authors: Colet, Josep Comín, Mainar, Antoni Sicras, Salazar-Mendiguchía, Joel, Del Campo Alonso, María Isabel, Echeto, Ainara, Larena, David Vilanova, Sánchez, Olga Delgado
Format: Article
Language:English
Subjects:
acenocoumarol
apixaban
cardiovascular events
cost–effectiveness
healthcare resources
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c412t-c41a21f9b9381ec8ef6f613a111e571dc321c0599be0731ae00e1e64928fe8263
container_end_page e230007
container_issue 8
container_start_page e230007
container_title Journal of comparative effectiveness research
container_volume 12
creator Colet, Josep Comín
Mainar, Antoni Sicras
Salazar-Mendiguchía, Joel
Del Campo Alonso, María Isabel
Echeto, Ainara
Larena, David Vilanova
Sánchez, Olga Delgado
description Healthcare resources usage and costs associated to nonvalvular atrial fibrillation (NVAF) were analyzed in Spain. This is an observational and retrospective study on patients with NVAF who started their treatment with apixaban or acenocoumarol between 1 January 2015 and 31 December 2017. 2160 patients treated with apixaban were paired (1:1) with patients treated with acenocoumarol (propensity score matching). Apixaban reduced the incidence of strokes and systemic embolisms, minor and major bleedings and deaths, versus acenocoumarol. Apixaban led to reductions of 80, 55 and 43% in costs related to nursing visits, hospitalizations, and emergency visits, respectively, leading to annual cost savings of €274/patient, from the perspective of society. Our results suggested that apixaban is a cost-effective alternative for patients with NVAF.
doi_str_mv 10.57264/cer-2023-0007
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_87a2b1a2918640ad801f9041d2d3edc9</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_87a2b1a2918640ad801f9041d2d3edc9</doaj_id><sourcerecordid>2841883088</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-c41a21f9b9381ec8ef6f613a111e571dc321c0599be0731ae00e1e64928fe8263</originalsourceid><addsrcrecordid>eNpVkc1vFSEUxYnR2ObZrUvD0s1UPuYD3BjTqG3SxIW6JneYO300PHgCM-p_L6-vvtgFcHM593cIh5DXnF12g-jbdxZTI5iQDWNseEbOBWtF00sun59q1p2Ri5zvq4L1qtWdeEnO5NAqrTt2TtZrBF-2FhLShDkuyWKmECZqYy61yjlaBwUn-suVLQ0xrODXxUOiUJIDT2c3Juc9FBcDdYF-24ML7yns3W8YIdAVU14qyWKINi47SNG_Ii9m8BkvHs8N-fH50_er6-b265ebq4-3jW25KIcdBJ_1qKXiaBXO_dxzCZxz7AY-WSm4ZZ3WI7JBckDGkGPfaqFmVKKXG3Jz5E4R7s0-uer-x0Rw5qER052BVJz1aNQAYqx2mqu-ZTApVo1ZyycxSZysrqwPR9Z-GXe1g6Ek8E-gT2-C25q7uBrOOqYk55Xw9pGQ4s8FczE7ly3WvwsYl2yEarlSktW1IZdHqU0x54TzyYcz8xC-qeGbQ_jmEH4dePP_607yf1HLv8gCrTA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2841883088</pqid></control><display><type>article</type><title>Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol</title><source>PubMed Central</source><creator>Colet, Josep Comín ; Mainar, Antoni Sicras ; Salazar-Mendiguchía, Joel ; Del Campo Alonso, María Isabel ; Echeto, Ainara ; Larena, David Vilanova ; Sánchez, Olga Delgado</creator><creatorcontrib>Colet, Josep Comín ; Mainar, Antoni Sicras ; Salazar-Mendiguchía, Joel ; Del Campo Alonso, María Isabel ; Echeto, Ainara ; Larena, David Vilanova ; Sánchez, Olga Delgado</creatorcontrib><description>Healthcare resources usage and costs associated to nonvalvular atrial fibrillation (NVAF) were analyzed in Spain. This is an observational and retrospective study on patients with NVAF who started their treatment with apixaban or acenocoumarol between 1 January 2015 and 31 December 2017. 2160 patients treated with apixaban were paired (1:1) with patients treated with acenocoumarol (propensity score matching). Apixaban reduced the incidence of strokes and systemic embolisms, minor and major bleedings and deaths, versus acenocoumarol. Apixaban led to reductions of 80, 55 and 43% in costs related to nursing visits, hospitalizations, and emergency visits, respectively, leading to annual cost savings of €274/patient, from the perspective of society. Our results suggested that apixaban is a cost-effective alternative for patients with NVAF.</description><identifier>ISSN: 2042-6305</identifier><identifier>EISSN: 2042-6313</identifier><identifier>DOI: 10.57264/cer-2023-0007</identifier><identifier>PMID: 37489950</identifier><language>eng</language><publisher>England: Becaris Publishing Ltd</publisher><subject>acenocoumarol ; apixaban ; cardiovascular events ; cost–effectiveness ; healthcare resources</subject><ispartof>Journal of comparative effectiveness research, 2023-08, Vol.12 (8), p.e230007-e230007</ispartof><rights>2023 The Authors 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c412t-c41a21f9b9381ec8ef6f613a111e571dc321c0599be0731ae00e1e64928fe8263</cites><orcidid>0000-0003-2171-8508 ; 0000-0002-8232-293X ; 0000-0002-6482-301X ; 0000-0001-8780-720X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508311/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508311/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37489950$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Colet, Josep Comín</creatorcontrib><creatorcontrib>Mainar, Antoni Sicras</creatorcontrib><creatorcontrib>Salazar-Mendiguchía, Joel</creatorcontrib><creatorcontrib>Del Campo Alonso, María Isabel</creatorcontrib><creatorcontrib>Echeto, Ainara</creatorcontrib><creatorcontrib>Larena, David Vilanova</creatorcontrib><creatorcontrib>Sánchez, Olga Delgado</creatorcontrib><title>Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol</title><title>Journal of comparative effectiveness research</title><addtitle>J Comp Eff Res</addtitle><description>Healthcare resources usage and costs associated to nonvalvular atrial fibrillation (NVAF) were analyzed in Spain. This is an observational and retrospective study on patients with NVAF who started their treatment with apixaban or acenocoumarol between 1 January 2015 and 31 December 2017. 2160 patients treated with apixaban were paired (1:1) with patients treated with acenocoumarol (propensity score matching). Apixaban reduced the incidence of strokes and systemic embolisms, minor and major bleedings and deaths, versus acenocoumarol. Apixaban led to reductions of 80, 55 and 43% in costs related to nursing visits, hospitalizations, and emergency visits, respectively, leading to annual cost savings of €274/patient, from the perspective of society. Our results suggested that apixaban is a cost-effective alternative for patients with NVAF.</description><subject>acenocoumarol</subject><subject>apixaban</subject><subject>cardiovascular events</subject><subject>cost–effectiveness</subject><subject>healthcare resources</subject><issn>2042-6305</issn><issn>2042-6313</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkc1vFSEUxYnR2ObZrUvD0s1UPuYD3BjTqG3SxIW6JneYO300PHgCM-p_L6-vvtgFcHM593cIh5DXnF12g-jbdxZTI5iQDWNseEbOBWtF00sun59q1p2Ri5zvq4L1qtWdeEnO5NAqrTt2TtZrBF-2FhLShDkuyWKmECZqYy61yjlaBwUn-suVLQ0xrODXxUOiUJIDT2c3Juc9FBcDdYF-24ML7yns3W8YIdAVU14qyWKINi47SNG_Ii9m8BkvHs8N-fH50_er6-b265ebq4-3jW25KIcdBJ_1qKXiaBXO_dxzCZxz7AY-WSm4ZZ3WI7JBckDGkGPfaqFmVKKXG3Jz5E4R7s0-uer-x0Rw5qER052BVJz1aNQAYqx2mqu-ZTApVo1ZyycxSZysrqwPR9Z-GXe1g6Ek8E-gT2-C25q7uBrOOqYk55Xw9pGQ4s8FczE7ly3WvwsYl2yEarlSktW1IZdHqU0x54TzyYcz8xC-qeGbQ_jmEH4dePP_607yf1HLv8gCrTA</recordid><startdate>20230801</startdate><enddate>20230801</enddate><creator>Colet, Josep Comín</creator><creator>Mainar, Antoni Sicras</creator><creator>Salazar-Mendiguchía, Joel</creator><creator>Del Campo Alonso, María Isabel</creator><creator>Echeto, Ainara</creator><creator>Larena, David Vilanova</creator><creator>Sánchez, Olga Delgado</creator><general>Becaris Publishing Ltd</general><general>Becaris Publishing Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-2171-8508</orcidid><orcidid>https://orcid.org/0000-0002-8232-293X</orcidid><orcidid>https://orcid.org/0000-0002-6482-301X</orcidid><orcidid>https://orcid.org/0000-0001-8780-720X</orcidid></search><sort><creationdate>20230801</creationdate><title>Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol</title><author>Colet, Josep Comín ; Mainar, Antoni Sicras ; Salazar-Mendiguchía, Joel ; Del Campo Alonso, María Isabel ; Echeto, Ainara ; Larena, David Vilanova ; Sánchez, Olga Delgado</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-c41a21f9b9381ec8ef6f613a111e571dc321c0599be0731ae00e1e64928fe8263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>acenocoumarol</topic><topic>apixaban</topic><topic>cardiovascular events</topic><topic>cost–effectiveness</topic><topic>healthcare resources</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Colet, Josep Comín</creatorcontrib><creatorcontrib>Mainar, Antoni Sicras</creatorcontrib><creatorcontrib>Salazar-Mendiguchía, Joel</creatorcontrib><creatorcontrib>Del Campo Alonso, María Isabel</creatorcontrib><creatorcontrib>Echeto, Ainara</creatorcontrib><creatorcontrib>Larena, David Vilanova</creatorcontrib><creatorcontrib>Sánchez, Olga Delgado</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Journal of comparative effectiveness research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Colet, Josep Comín</au><au>Mainar, Antoni Sicras</au><au>Salazar-Mendiguchía, Joel</au><au>Del Campo Alonso, María Isabel</au><au>Echeto, Ainara</au><au>Larena, David Vilanova</au><au>Sánchez, Olga Delgado</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol</atitle><jtitle>Journal of comparative effectiveness research</jtitle><addtitle>J Comp Eff Res</addtitle><date>2023-08-01</date><risdate>2023</risdate><volume>12</volume><issue>8</issue><spage>e230007</spage><epage>e230007</epage><pages>e230007-e230007</pages><issn>2042-6305</issn><eissn>2042-6313</eissn><abstract>Healthcare resources usage and costs associated to nonvalvular atrial fibrillation (NVAF) were analyzed in Spain. This is an observational and retrospective study on patients with NVAF who started their treatment with apixaban or acenocoumarol between 1 January 2015 and 31 December 2017. 2160 patients treated with apixaban were paired (1:1) with patients treated with acenocoumarol (propensity score matching). Apixaban reduced the incidence of strokes and systemic embolisms, minor and major bleedings and deaths, versus acenocoumarol. Apixaban led to reductions of 80, 55 and 43% in costs related to nursing visits, hospitalizations, and emergency visits, respectively, leading to annual cost savings of €274/patient, from the perspective of society. Our results suggested that apixaban is a cost-effective alternative for patients with NVAF.</abstract><cop>England</cop><pub>Becaris Publishing Ltd</pub><pmid>37489950</pmid><doi>10.57264/cer-2023-0007</doi><orcidid>https://orcid.org/0000-0003-2171-8508</orcidid><orcidid>https://orcid.org/0000-0002-8232-293X</orcidid><orcidid>https://orcid.org/0000-0002-6482-301X</orcidid><orcidid>https://orcid.org/0000-0001-8780-720X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2042-6305
ispartof Journal of comparative effectiveness research, 2023-08, Vol.12 (8), p.e230007-e230007
issn 2042-6305
2042-6313
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_87a2b1a2918640ad801f9041d2d3edc9
source PubMed Central
subjects acenocoumarol
apixaban
cardiovascular events
cost–effectiveness
healthcare resources
title Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T20%3A09%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Healthcare%20resources%20and%20costs%20associated%20with%20nonvalvular%20atrial%20fibrillation%20in%20Spain:%20apixaban%20versus%20acenocoumarol&rft.jtitle=Journal%20of%20comparative%20effectiveness%20research&rft.au=Colet,%20Josep%20Com%C3%ADn&rft.date=2023-08-01&rft.volume=12&rft.issue=8&rft.spage=e230007&rft.epage=e230007&rft.pages=e230007-e230007&rft.issn=2042-6305&rft.eissn=2042-6313&rft_id=info:doi/10.57264/cer-2023-0007&rft_dat=%3Cproquest_doaj_%3E2841883088%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c412t-c41a21f9b9381ec8ef6f613a111e571dc321c0599be0731ae00e1e64928fe8263%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2841883088&rft_id=info:pmid/37489950&rfr_iscdi=true